ZITUVIO (Sitagliptin) Patent Expiration, LOE Window & CMS Spending

ZITUVIO (Sitagliptin) by Zydus Lifesciences Global Fze: FDA Orange Book core substance LOE 2035-02-25, 3 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorZydus Lifesciences Global Fze
FDA Application & PathwayN211566 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-02-25
Last Listed Patent or Exclusivity Date2035-02-25
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel